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Abstract: Levetiracetam is a broad-spectrum antiepileptic drug commonly used in intensive care
units (ICUs). The objective of this study is to evaluate the adequacy of levetiracetam dosing in
patients with normal or augmented renal clearance (ARC) admitted to the ICU by population
modelling and simulation. A multicentre prospective study including twenty-seven critically ill
patients with urinary creatinine clearance (CrCl) > 50 mL/min and treated with levetiracetam
was developed. Levetiracetam plasma concentrations were best described by a two-compartment
model. The parameter estimates and relative standard errors (%) were clearance (CL) 3.5 L/h (9%),
central volume of distribution (V1) 20.7 L (18%), intercompartmental clearance 31.9 L/h (22%), and
peripheral volume of distribution 33.5 L (13%). Interindividual variability estimates were, for the CL,
32.7% (21%) and, for V1, 56.1% (29%). The CrCl showed significant influence over CL. Simulations
showed that the administration of at least 500 mg every 8 h or 1000 mg every 12 h are needed in
patients with normal renal function. Higher doses (1500 or 2000 mg, every 8 h) are needed in patients
with ARC. Critically ill patients with normal or ARC treated with levetiracetam could be at high risk
of being underdosed.
Keywords: levetiracetam; augmented renal clearance; intensive care; critically ill patients; population
pharmacokinetic; modelling; Monte Carlo simulations; seizure
1. Introduction
Levetiracetam is a broad-spectrum antiepileptic drug with proven efficacy in treating
multiple seizure types, in both the adult and paediatric population. Because of its improved
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safety profile and ease of use compared to other conventional antiepileptic drugs such
as phenytoin, it is frequently used in the treatment of status epilepticus and in seizure
prophylaxis after a neurologic injury, being a commonly used treatment in intensive care
units (ICUs) [1–3].
Levetiracetam has a linear pharmacokinetic profile. It is rapidly and almost completely
absorbed when administered orally, with a time to reach the peak concentration (Tmax) of
1–2 h and a high bioavailability (>95%). Its apparent volume of distribution is 0.5–0.7 L/kg
with non-significant plasma protein binding (<3%). Renal clearance represents the main
elimination mechanism with a 66% of the dose excreted unchanged in urine, which leads
to a good correlation between levetiracetam clearance and a patient‘s creatinine clearance
(CrCl). Additionally, a fraction of the dose (24%) is eliminated by metabolism through
enzymatic hydrolysis of the acetamide group, carried out by a type B esterase, mainly
in blood. Clinically relevant interactions are not expected, as this metabolic pathway is
only responsible for the metabolism of a small part of the administered dose. Additionally,
levetiracetam does not induce or inhibit CYP enzymes resulting in minimal drug-drug
interactions. The metabolites have no known pharmacological activity and are renally
excreted [1,4,5].
There is no clear correlation between levetiracetam serum concentration and efficacy
or tolerability. The current reference range for trough concentrations is 12–46 mg/L [6],
although some authors have proposed a more modest target range of 6–20 mg/L [7]. The
favourable pharmacokinetic profile together with the absence of major drug interactions
and broad therapeutic window makes routine therapeutic drug monitoring (TDM) unnec-
essary. However, TDM, as a way to ensure effective and safe exposures, may be indicated
in certain circumstances, such as in patients with altered levetiracetam clearance. This is
the case of elderly patients, children, pregnant women, patients with renal insufficiency or
critically ill patients [8,9].
In fact, the pharmacokinetic behaviour of levetiracetam has been poorly studied
in critically ill patients with augmented renal clearance (ARC). The ARC, defined as a
CrCl > 130 mL/min/1.73 m2, is present in 20–65% of critically ill patients, being more
common in certain conditions, such as traumatic brain injury (TBI) (85%) or subarachnoid
haemorrhage (SAH) (100%). Although the physiological mechanism responsible for ARC
in critically ill patients is not well-defined, the combination of systemic inflammation
coupled with a greater renal functional reserve and together with intensive fluid therapy
and the administration of inotropic and vasopressor drugs could explain this phenomenon.
The presence of ARC could lead to faster elimination of renally excreted drugs, such as
levetiracetam, potentially resulting in subtherapeutic concentrations and poorer clinical
outcomes [10–13].
In this regard, the aim of this study is to evaluate the adequacy of levetiracetam dosing
for the achievement of therapeutic levels in patients with normal or high renal clearance
admitted to the ICU by the characterization of the levetiracetam pharmacokinetics by
population modelling and simulation.
2. Materials and Methods
2.1. Study Design and Patient Population
A multicentric open-label prospective study was conducted in critically ill patients
admitted to the ICUs of Araba University Hospital (Vitoria-Gasteiz, Spain) and Doce de
Octubre Hospital (Madrid, Spain). Patients were recruited during 2019 and 2020 follow-
ing a protocol previously approved by the Basque Clinical Research Ethics Committee
(EPA2018019 (SP)). The study was carried out in accordance with ICH Guidelines for Good
Clinical Practice. Samples and data from patients were provided by the Basque Biobank
(www.biobancovasco.org) and were processed following standard operation procedures
with appropriate ethical approval. ICU patients were eligible if they were treated with
levetiracetam and had a CrCl > 50 mL/min measured in urine. The exclusion criteria were
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age less than 18 years, pregnancy or hypersensitivity to the active substance or to any of
the excipients.
2.2. Drug Administration, Sampling Procedure and Analytical Method
Each patient received a dose of 500, 1000 or 1500 mg of levetiracetam every 12 h, as
a 30-min intravenous infusion. For each patient, blood samples (3 mL) were taken at 0 h
(pre-dose), at the end of the infusion (0.5 h) and at the end of the dosing interval (12 h).
Moreover, one sample was taken within the intervals of 1–2 h, 3–5 h and 6–8 h after drug
administration. Each sample was immediately centrifuged at 3000 rpm for 10 min to collect
the plasma, which was immediately frozen at −20 ◦C. Within the following week, samples
were stored at −80 ◦C until analysis.
Plasma concentrations of levetiracetam were quantified with a high-performance
liquid chromatography (HPLC) assay with ultraviolet detection at a wavelength of 205 nm.
The method was validated following the US Food and Drug Administration (FDA) (2018)
and the European Medicines Agency (EMA) (2012) guidelines. Separation was performed
on a Symmetry® C18 (4.6 mm × 150 mm × 5 µm) column (Waters, Milford, Massachusetts,
United States) eluted with ammonium phosphate and acetonitrile (95:5, v:v) mobile phase
and it was delivered at 1.2 mL/min. Sample preparation consisted of protein precipitation
with acetonitrile and centrifugation for 10 min at 15,000× g. The supernatants were then
injected into the HPLC system.
The assay was linear over the concentration range from 2 to 100 mg/L. Specificity
was assessed using six blank standards and lower limit of quantification (LLOQ) level
samples. The chromatograms were checked for interference, with no interference peaks
detected at the retention time of levetiracetam. Intra–batch and inter–batch accuracy and
precision were evaluated at four different concentration levels (LLOQ and low, middle,
and high-quality control) in six replicates. The intra–day and inter–day coefficients of
variation (CV) and bias were never above 15%. Stock solution stability, the stability of
levetiracetam in storage conditions (at −20 ◦C for one month and at −80 ◦C for one
year), freeze–thaw stability of the analyte in the matrix from freezer storage conditions
to room temperature, and auto-sampler rack stability were also evaluated and confirmed.
Levetiracetam substance for standards and quality controls was a reference standard,
United States Pharmacopoeia, USP.
2.3. Noncompartmental Analysis
PK parameters for levetiracetam were initially explored by noncompartmental anal-
ysis using Phoenix 64 (Build 8.3.0.5005, Certara, Princeton, NJ, USA). The following PK
parameters were provided for levetiracetam: the area under the concentration-time curve
within the dosing interval (AUC12), peak plasma concentration (Cmax), apparent systemic
clearance (CL), elimination half-life (t1/2) and apparent volume of distribution (Vz). Area
under the concentration-time curve was calculated using the linear-log trapezoidal rule.
Afterwards, the correlation between clearance and CrCl at an individual level was explored.
Statistical analysis was performed with IBM® SPSS® Statistics for Windows, Version
26. Student t tests were used to compare the pharmacokinetic parameters of levetiracetam
between patients in different groups. Statistical significance was assessed at p < 0.05.
2.4. Pharmacometric Modelling
Nonlinear mixed-effects modelling was implemented in NONMEM (v.7.4), using
first-order conditional estimation method with interaction (FOCE+I). On the basis of visual
exploration of the data and a review of the literature, one- and two-compartment models
were considered to describe the levetiracetam concentration-time data. Regarding the
variability model, interindividual variability (IIV) associated with the structural pharma-
cokinetic parameters was modelled exponentially, whereas the residual variability was
tested as either proportional, additive or combined error model. The significance of the
off-diagonal elements of the Ω variance–covariance matrix was also explored.
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Selection between models was based on the following criteria. First, biological plau-
sibility. Second, a significant reduction in the objective function value (OFV = −2 ×
log-likelihood). Third, the precision of the parameter estimation expressed as the rela-
tive standard error (RSE [%]) and calculated as the ratio between the standard error and
the parameter estimate. Fourth, visual inspection of the goodness-of-fit (GOF) plots, in-
cluding the observed versus individual and population predicted concentration and the
residuals plots.
The covariates assessed at baseline evaluated in the analysis included demographic
factors (sex, age, height and serum albumin), CrCl (measured in urine), blood chemistry
(glucose, albumin, total bilirubin, haemoglobin and leukocytes), acute physiology and
chronic health evaluation (APACHE II) and diagnosis. Random effects associated with
parameters of interest were plotted versus covariates to explore potential relationships and
the Stepwise Covariate Model building tool of Perl speaks NONMEM (v.4.8) was performed
as a preliminary selection of covariates. Categorical covariates were modelled as a shift
in the typical value for the least common categories, whereas continuous covariates were
modelled using linear, exponential or power functions after centring on the median. CrCl
was explored as a continuous covariate, but it was also dichotomized into two groups,
CrCl < 130mL/min or CrCl ≥ 130 mL/min. Covariates were retained in the model if
their inclusion produced a significant decrease of the OFV ≥ 3.84 units (equivalent to
p < 0.05 for one degree of freedom) in comparison with the previous model without
the covariate. This forward inclusion approach was followed by its reverse (backward
elimination) removing those covariates, whose elimination did not produce a significant
increase of the OFV ≤ 6.63 (equivalent to p > 0.01 for one degree of freedom). Therefore,
when all the statistically significant covariates were added to the model, each of them was
individually removed. If the removal of a covariate was found not to be significant it was
dropped in favour of the simpler model.
2.5. Final Model Evaluation
GOF plots were used as the first indicator of goodness-of-fit, including the plotting of
model-based individual predictions (IPRED) and population predictions (PRED) versus
the observed concentrations (DV), conditional weighted residual errors (CWRES) vs time
after dose (TAD) and the CWRES vs PRED. The parameter precision was evaluated by
running a 2000 sample bootstrap (PsN v.4.8). Finally, a simulation-based model diagnostic
to study the performance of the final model, a prediction-corrected Visual Predictive Check
(pcVPC), was constructed by replicating 1000 studies with the same design as the original
clinical study and representing the 10th, 50th, and 90th percentiles of the observed data
and the 95% confidence intervals for the mentioned predicted percentiles, based on the
simulated data sets.
2.6. Dosing Simulations
Using the same dosing regimens administered to patients, 1000 subjects with dif-
ferent CrCl were simulated (80, 120, 160, 200 and 240 mL/min) to evaluate the impact
of the covariate on the levetiracetam clearance. Moreover, stochastic simulations were
performed to predict levetiracetam plasma minimum concentrations (Cmin) under various
dosing regimens (doses from 500 mg to 2000 mg given at either 12- or 8-h intervals, as
a 30-min intravenous infusion) and to estimate the probability of target attainment. The
target trough concentrations were 12 to 46 mg/L at steady state as recommended by the
International League Against Epilepsy (ILAE). A lower target trough range (>6 mg/L)
was also investigated. Simulations with the final model were performed with 1000 virtual
subjects with CrCl values within the range from 80 to 240 mL/min. CrCl cut-off values
were selected based on the observed distribution of CrCl values of the population included
in the study and on the summary of product characteristics of levetiracetam, where dosage
adjustments are recommended for CrCl below 80 mL/min, but not above this threshold [1].
Pharmaceutics 2021, 13, 1690 5 of 14
Simulations extending infusion time to 2 h were performed in those situations in which
target attainment with a minimum probability of 80% was not reached.
3. Results
3.1. Patient Demographics
Twenty-seven critically ill patients were included in the study. The main diagnoses
were haemorrhagic strokes (n = 10), trauma (n = 8) or other diagnostics such as meningitis,
space occupying lesions, convulsive crisis, encephalopathy, arteriovenous malformations
or low level of consciousness. Subject characteristics are described in Table 1. A total of
158 plasma samples were analysed, with a median of six, and a minimum of five, plasma
samples per patient. Most of the patients (18 out of 27) were treated with 500 mg/12 h of
levetiracetam and 10 presented ARC. Levetiracetam was well tolerated, as no evidence
of adverse events was recorded, even with the highest dose. Concentration versus time
profile of levetiracetam in all the patients is represented in Figure 1.
Table 1. Characteristics of the population included in the study.
Covariate N (%) Median (Range)
Sex:
• Male 18 (67) -
• Female 9 (33) -
ARC (CrCl > 130 mL/min):
• Yes 10 (37)
• No 17 (63)
Diagnostic:
• Haemorrhagic strokes 10 (37) -
• Trauma 8 (30) -
• Others 9 (33) -
Age (years) - 60 (23–81)
Weight (kg) - 80 (58–115)
Height (cm) - 168 (148–189)
BSA (m2) 1 - 1.9 (1.59–2.33)
APACHE II - 18 (5–35)
CrCl (mL/min) 2 - 117 (54–239)
Glucose (mg/dL) - 142 (91–337)
Albumin (g/dL) - 3.4 (2.1–3.9)
Total bilirubin (mg/dL) - 0.6 (0.2–2.1)
Hemoglobin (g/dL) - 11.6 (6.7–14.5)
Leukocytes (109/L) - 10.4 (3–24.6)
APACHE: acute physiology and chronic health evaluation; ARC: Augmented renal clearance; BSA: Body Surface
Area; CrCl: creatinine clearance. 1 Body surface area (Du Bois method) = 0.007184 × Height 0.725 × Weight 0.425.
2 Creatinine clearance= [Urine creatinine (mg/dL) × Volume of urine per minute (mL/min)]/Creatinine plasma
level (mg/dL).
3.2. Noncompartmental Analysis
Pharmacokinetic parameters obtained with noncompartmental analysis are summa-
rized in Table 2. The dose-normalized Cmax and CL were significantly higher in patients
with ARC than in those with normal CrCl (p > 0.05). Figure 2 shows the correlation between
CrCl and levetiracetam clearance calculated by noncompartmental analysis.
3.3. Population Pharmacokinetic Modelling
Plasma concentrations were best described by a two-compartment linear model,
characterized by drug total body clearance (CL), central volume of distribution (V1),
peripheral volume of distribution (V2) and intercompartmental clearance (Q). IIV was
exponentially included for CL and V1, and no correlation was detected between the
random effects associated with the pharmacokinetic parameters. Residual variability was
proportionally modelled. The goodness of fit of the base model was verified by GOF plots.
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Both the CrCl, as a continuous variable, and the ARC, as a categorical covariate
showed significant influence over CL. CrCl was selected for the final model since the
reduction in IIV was greater than with the categorical variable (5.6% vs 3.9%). trauma
vs non-trauma diagnosis and APACHE II also showed influence over V1. However, they
were eventually excluded from the final model since their individual deletion did not
significantly increase the OFV. Therefore, the final model only considered the CrCl as a
covariate of the total clearance.









V1(L) = 20.7 × eη2
where CL is clearance, CrCl is urinary creatinine clearance, V1 is central volume of dis-
tribution, η1 and η2 represent the interindividual variability for CL, and V1, respectively,
which followed normal distributions with a mean of 0.
Inclusion of the CrCl on the CL decreased the unexplained IIV of CL from 38.3% in
the base model to 32.7% in the final model and a statistically significant drop of the OFV
was obtained with respect to the base model (∆OFV > 6.63). The population PK model
and the results of the bootstrap analysis are shown in Table 3. The residual standard
errors revealed that all parameters were precisely estimated. Moreover, the estimates
of the parameters were very similar to the median values obtained from the bootstrap
analysis. Figure 3 displays the GOF plots for the final model. Figure 4 shows the correlation
found between CrCl and levetiracetam clearance. The pcVPC, provided in Figure 5,
confirmed that the model appropriately predicts both central tendency and variability of
the observed concentrations.
Table 3. Base and final population pharmacokinetic models estimates, shrinkage a values and
bootstrap results.





CL (L/h) = θnr +
(CrCl/120)θr 4.6 (8) -
θnr - 3.5 (9) 3.5 (2.8–4.1)
θr 2.5 (17) 2.5 (0.9–3.9)
V1 (L) 20.8 (18) 20.7 (18) 20.8 (13.4–27.7)
Q (L/h) 31.4 (21) 31.9 (22) 30.9 (22.5–47.8)
V2 (L) 34.1 (14) 33.5 (13) 34.2 (19.9–45.4)
IIV_CL (%) 38.3 (19) 32.7 (21) 30.7 (20.2–48.3)
IIV_V1 (%) 54.4 (29) 56.1 (29) 58.0 (22.6–114.0)
RE_proportional (%) 22.3 (15) 22.3 (15) 21.5 (15.7–27.7)
CL, clearance; CrCl, creatinine clearance; V1, central volume of distribution; Q, intercompartmental clearance; V2,
peripheral volume of distribution; IIV, inter-individual variability; RE, Residual error; RSE, Relative standard
errors; CI, Confidence interval. a CL ηsh = 2%; V1 ηsh = 23%; εsh = 12%.
3.4. Dosing Simulations
Tables 4 and 5 show the probability of target attainment for simulated patients with
different CrCl, calculated as the percentage of virtual subjects (n = 1000) who had leve-
tiracetam trough concentrations above the previously defined values. Considering the
target of trough concentrations higher than 12 mg/L, with the twice daily dosing regimen,
probabilities higher than 80% were only obtained in patients with no ARC and with the
highest doses. More specifically, doses of 1500 mg and 2000 mg every 12 h would be
needed for patients with CrCl of 80 and 120 mL/min, respectively. In patients with CrCl
of 160 and 200 mL/min, dosing schedules with 8-h interval would be needed (doses of
1500 and 2000 mg, respectively). With those dosing regimens, the probability of Cmin to
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exceed the value of 46 mg/L is low (<5%) in the respective group of patients. Notably,
in patients with CrCl of 240 mL/min the targeted minimum concentration of 12 mg/L
was not reached even with doses of 2000 mg every 8 h. Extending the infusion time of the
2000 mg dose to 2 h in this group, did not increase enough the probability of reaching the
targeted minimum concentration of 12 mg/L (from 59% to 67%).




Figure 3. The goodness of fit plots of individual predicted (IPRED) versus the observed (DV) le-
vetiracetam concentrations (top-left), population predicted (PRED) versus DV levetiracetam con-
centrations (top-right), conditional weighted residuals (CWRES) versus PRED (bottom-left) and 
CWRES versus time after dose (bottom-right) of the final model. 
 
Figure 4. Plot of the individual predicted levetiracetam clearances (CL) estimated by population 
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Figure 4. Plot of the individual predicted levetiracetam clearances (CL) estimated by population PK
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3.4. Dosing Simulations 
Tables 4 and 5 show the probability of target attainment for simulated patients with 
different CrCl, calculated as the percentage of virtual subjects (n = 1000) who had le-
vetiracetam trough concentrations above the previously defined values. Considering the 
target of trough concentrations higher than 12 mg/L, with the twice daily dosing regimen, 
probabilities higher than 80% were only obtained in patients with no ARC and with the 
highest doses. More specifically, doses of 1500 mg and 2000 mg every 12 h would be 
needed for patients with CrCl of 80 and 120 mL/min, respectively. In patients with CrCl 
of 160 and 200 mL/min, dosing schedules with 8-hour interval would be needed (doses of 
1500 and 2000 mg, respectively). With those dosing regimens, the probability of Cmin to 
exceed the value of 46 mg/L is low (<5%) in the respective group of patients. Notably, in 
patients with CrCl of 240 mL/min the targeted minimum concentration of 12 mg/L was 
not reached even with doses of 2000 mg every 8 h. Extending the infusion time of the 2000 
mg dose to 2 hours in this group, did not increase enough the probability of reaching the 
targeted minimum concentration of 12 mg/L (from 59% to 67%). 
When considering the lower target trough concentrations of >6 mg/L twice daily dos-
ing regimens were able to reach the therapeutic interval with a probability greater than 
80%, except in patients with CrCl of 240 mL/min, in which dosing every 8 hours seemed 
mandatory. In detail, 1000 mg every 12 h would be suitable for patients with normal renal 
function, 1500 mg every 12 h for patients with CrCl of 160 mL/min, 2000 mg every 12 h 
for patients with CrCl of 200 mL/min and 1500 mg every 8 h for patients with CrCl of 240 
mL/min. 
  
Figure 5. Prediction-corrected visual predictive check of the final model. The dots represent the prediction–corrected concen-
trations (mg/L). The continuous line represents the 10th, 50th and 90th observed percentiles. Simulation-based 95% confi-
dence intervals for the median and the 10th and 90th percentiles are displayed by dark and light grey shading, respectively.
Table 4. Probability of target attai ment based on simulations of the final population model with different doses adminis-
tered every 12 h. In bold are represented those probabilities ≥80%.
CrCl (mL/min) Dose (mg) PerfusionDuration (min)
Daily Dose
(mg)
Probability of Cmin (%)
>6 mg/L >12 mg/L >46 mg/L
Twice Daily (Tau = 12 h)
80 500 30 1000 62 12 0
1000 30 2000 93 60 0
1500 30 3000 99 85 3
2000 30 4000 100 94 14
120 500 30 1000 43 6 0
1000 30 2000 86 43 0
1500 30 3000 95 72 2
2000 30 4000 98 85 6
160 500 30 1000 22 1 0
1000 30 2000 67 22 0
1500 30 3000 87 51 0
2000 30 4000 94 69 2
200 1000 30 2000 39 6 0
1500 30 3000 68 25 0
2000 30 4000 80 42 0
240 1500 30 300 37 7 0
2000 30 4000 55 15 0
Cmin, Minimum levetiracetam concentration; CrCl, creatinine clearance; Tau, dosing interval.
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Table 5. Probability of target attainment based on simulations of the final population model with different doses adminis-
tered every 8 h. In bold are represented those probabilities ≥80%.
CrCl (mL/min) Dose (mg) PerfusionDuration (min)
Daily Dose
(mg)
Probability of Cmin (%)
>6 mg/L >12 mg/L >46 mg/L
Three Times Daily (Tau = 8 h)
80 500 30 1500 94 51 0
1000 30 3000 100 93 5
1500 30 4500 100 99 31
120 500 30 1500 84 33 0
1000 30 3000 99 84 2
1500 30 4500 100 96 17
160 500 30 1500 65 12 0
1000 30 3000 94 65 0
1500 30 4500 99 89 5
2000 30 6000 100 97 17
200 500 30 1500 38 4 0
1000 30 3000 83 39 0
1500 30 4500 95 69 1
2000 30 6000 98 84 5
240 1000 30 3000 61 15 0
1500 30 4500 80 38 0
2000 30 6000 89 59 1
2000 120 6000 94 67 1
Cmin, Minimum levetiracetam concentration; CrCl, creatinine clearance; Tau, dosing interval.
When considering the lower target trough concentrations of >6 mg/L twice daily
dosing regimens were able to reach the therapeutic interval with a probability greater
than 80%, except in patients with CrCl of 240 mL/min, in which dosing every 8 h seemed
mandatory. In detail, 1000 mg every 12 h would be suitable for patients with normal renal
function, 1500 mg every 12 h for patients with CrCl of 160 mL/min, 2000 mg every 12 h
for patients with CrCl of 200 mL/min and 1500 mg every 8 h for patients with CrCl of
240 mL/min.
4. Discussion
In this study, a population pharmacokinetic model of levetiracetam in critically ill
patients was developed, for a better selection or optimization of the dose regimen, with
special focus on ARC condition. ICU patients commonly show altered pharmacokinetics
due to their intrinsic heterogeneity and the disease status that can lead to suboptimal
drug concentrations. In fact, the high variability observed in levetiracetam concentrations,
partially explained by patients’ renal function, suggested the need for dosing optimization
in patients with ARC and Monte Carlo simulations revealed the need of high doses to
attain the target concentrations.
The ARC condition has recently drawn attention due to its prevalence (present in
20–65% of the patients [10,14] in the intensive care setting), and its potential impact on
the elimination of the drugs, especially those primarily eliminated by renal excretion.
Pharmacokinetics of renally excreted antimicrobials, such as vancomycin, β-lactams or
linezolid, have demonstrated to be significantly modified in patients with ARC [15–19],
leading to sub-therapeutic concentrations. In this regard, clinicians should routinely assess
the renal function of critically ill patients, by measuring urinary CrCl, not only with the
aim of detecting renal impairment, but also, to detect ARC, in order to adjust drug doses.
Levetiracetam is a widely used drug in ICUs, both in treatment and in prophylaxis
of seizures, and is mainly excreted unchanged in urine (66%) making it vulnerable to
suffer from increased elimination in patients who display ARC. Nevertheless, the effect
of ARC on levetiracetam serum concentrations has been poorly investigated. In a case
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report, Cook et al. described a 22-year-old girl with severe TBI who displayed ARC. The
patient presented a higher than usual systemic clearance of levetiracetam and required
significantly higher dose [20].
In a study published by Spencer et al. [21], in 12 neurocritical care patients requiring
seizure prophylaxis who received 500 mg twice daily, they found a higher levetiracetam
clearance and a shorter half-life, compared with previously published results in healthy
volunteers. ARC was not present in their population, but there was a statistically significant
relationship between the systemic clearance of levetiracetam and estimated CrCl. Just
one patient with renal impairment (CrCl 42 mL/min), achieved a steady-state trough
concentration greater than 6 mg/L. Recently, two population pharmacokinetic models
of levetiracetam in neurocritical patients have been published [22,23]. Sime et al. [22]
developed a population pharmacokinetics model in 30 critically ill patients with TBI or
SAH without renal disfunction. ARC (urinary CrCl > 130 mL/min/1.73 m2) was present
in 70% of the patients. Urinary CrCl was found as a covariate that significantly influences
levetiracetam clearance, whereas body surface area (BSA) was found to influence leve-
tiracetam clearance, volume of distribution and the absorption rate constant. For every
40 mL/min/1.73 m2 increase in urinary CrCl, levetiracetam clearance increased by 50%
and the median trough concentrations were reduced by 50%. They performed dosing
simulations with dosages ranging from 1000 mg every 12 h to 2000 mg every 8 h and
concluded that for urinary CrCl greater than 120 mL/min/1.73 m2, none of the simulated
regimens had a probability of 80% or above of achieving trough concentrations higher
than 12 mg/L. Similarly, Ong et al. [23] have recently developed a population pharma-
cokinetics model in 20 neurosurgical patients with TBI, SAH or brain tumour resection.
ARC (estimated CrCl > 150 mL/min/1.73 m2) was present in 30% of the patients. In this
study, no covariates were found to significantly influenced levetiracetam pharmacokinetic
parameters. They also performed Monte Carlo simulations showing a low probability of
reaching trough concentrations > 6 mg/L with the 500 mg twice daily dosing regimen. A
dose of 1000 mg twice daily was required to achieve a probability of 80%.
In our study, the pharmacokinetics of levetiracetam were best described by a two-
compartment model, agreeing with that reported by Sime et al. [22] and Ong et al. [23].
None of the variables analysed had a significant influence on V1. Trauma diagnosis showed
statistical significance at a level of p < 0.05, but not at the level of p < 0.01, probably because
of the scarce number of patients presenting this diagnosis (n = 10), and thereby; was not
retained in the final model. Other authors have found significant influence of BSA [22,24] or
body weight [25] in levetiracetam V1 and/or CL. In a systematic review about levetiracetam
pharmacokinetics [25] in paediatric population, healthy subjects or non-critically ill adults,
great differences in the volume of distribution, with values from 33 L to 69.9 L (calculated
for a 75 kg subject), were reported. In our study, the total volume of distribution was 54.9 L,
in the range of most studies, although higher than that observed by Sime et al. (32 L) and
Ong et al. (37.2 L) [22,23].
In our model, the levetiracetam CL was only dependent on CrCl, which had a great
influence on patients with ARC (mean levetiracetam CL increased from 4.5 L/h to 9.2 L/h
in patients with CrCl from 120 to 240 mL/min). Sime et al. [22] also included CrCl as
a covariate for CL. However, for similar values of CrCl, their model estimates higher
levetiracetam clearance. The discrepancies observed between both models could, in part,
be due to the differences among the recruited subjects; Sime et al. [22] included only TBI
and SAH patients, whereas our population was more heterogeneous according to diagnosis,
and also, to age, body weight and CrCl. Ong et al. [23] found similar levetiracetam clearance
to that found in our study (3.6 vs. 4.1 L/h for a mean CrCl of 100 mL/min), however, they
could not include CrCl as a covariate. This may be, in part, because the subjects included
in their study had a narrower range of CrCl than our patients. Moreover, it has to be
considered that their patients’ renal function was estimated according to equations, instead
of being based on CrCl measured in urine.
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Despite the differences in the in the PK parameters, all studies bring out the risk of
not achieving the target concentrations in ARC patients. Currently, the most accepted
target is to achieve trough concentrations between 12 and 46 mg/L, proposed by ILAE [6],
although other authors have proposed lower values. This is the case of the Norwegian
Association of Clinical Pharmacology, which recommends target trough concentrations of 5
to 41 mg/L [26]. While ILAE recommendations are based on a retrospective database study
that only included the highest doses used by each patient [3], the latter also considered
other studies (globally 45% of all samples were below 12 mg/L, and 80% of all samples
were between 5 and 25 mg/L) [26]. Moreover, other authors also propose a target trough
range of 6–20 mg/L based on typical concentrations values reached with doses ranging
from 500 to 1500 mg every 12 h [7].
In our study, a dose of 500 mg every 12 h has shown to be insufficient in critical
patients with normal or augmented renal function. In fact, 100% and 67% of these patients
had at least one sub-therapeutic level considering the threshold of 12 mg/L or 6 mg/L,
respectively. Our results corroborate the need for dose optimization, as the risk for under
dosing is highly variable and dependent on the dosing regimen and the renal function of
the patients.
Monte Carlo simulations showed that the maximum dose approved in the summary
of product characteristics (1500 mg every 12 h) only guarantees to achieve trough concen-
tration of 12 mg/L in critically ill patients with CrCl ≤ 80 mL/min. In fact, the probability
to achieve target trough concentrations higher than 12 mg/L is very low in ARC patients
receiving levetiracetam in a twice daily dosing. Doses of 1500 mg and 2000 mg every 8 h
are needed to achieve probabilities >80% for individuals with CrCl ≥ 160 and 200 mL/min,
respectively, while in patients with CrCl of 240 mL/min, or higher this objective was not
reached, even with 2000 mg every 8 h. Several studies have proposed prolonged or continu-
ous infusion to ensure therapeutic concentrations of drugs in patients with ARC [19,27]. We
evaluated in patients with CrCl ≥ 240 mL/min if the probability of achieving Cmin target
would improve by prolonging the infusion time to 2 h. Monte Carlo simulation showed
only a mild improvement. Longer infusions were not studied due to concerns about the
stability of levetiracetam solutions at room temperature beyond 4 h [28]. When considering
the target trough concentrations of 6 mg/L, probabilities greater than 80% were obtained
with 1500 mg every 12 h only for patients with CrCl up to 160 mL/min. Sime et al. [22]
reported worse results in their population, as they concluded that even with doses as
high as 6 g of levetiracetam per day, trough concentrations within the currently accepted
target range were not guaranteed. Therefore, further studies are needed in order to better
elucidate the optimal dosing regimen in this population. Moreover, although the role
of TDM of levetiracetam has not yet been established, its use in ascertaining compliance
and managing patients that are at risk of being over- or under-dosed, such as critically ill
patients, would be surely helpful. In addition, it is important to bear in mind that ARC is
a dynamic a temporary situation [10], and accordingly, the renal function of the patients
should be daily evaluated in order to adjust dosing regimens if needed.
This study has several limitations. Firstly, this study enrolled a relatively small number
of patients, leading to a lack of external validation of the population PK model and limited
statistical power. Previous studies were also carried out with a similar number of patients
(20–30 patients) [22,23], but a larger sample could allow including any other covariates able
to explain some of the remaining variability. In any case, accurate and precise estimates of
all parameters were obtained, since a rich sampling strategy was followed in our study.
Finally, the lack of consensus about the trough concentration target is a point to address.
It would be advisable to determine a well-defined and universally accepted therapeutic
range, although it is difficult to establish a correlation between drug concentration and
clinical efficacy when levetiracetam is administered prophylactically to prevent seizures.
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5. Conclusions
A population pharmacokinetic model has been developed for levetiracetam in criti-
cally ill patients with normal or ARC. The pharmacokinetics of the drug were best described
by a two-compartment model and CrCl was found to have a significant effect on levetirac-
etam clearance, which can lead to a high risk of under-exposure, especially in patients
with ARC. According to our results, the administration of 500 mg every 12 h could not
be enough to achieve the target plasma concentration in the studied population. At least
500 mg every 8 h or 1000 mg every 12 h could be needed in patients with normal renal
function. Even the maximum dose approved in the summary of product characteristics
(1500 mg every 12 h) could be insufficient in the presence of ARC. However, further studies
with a greater number of patients are necessary to determine effective and safety dose
regimens in ARC patients.
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